The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation

Bibliographic Details
Main Authors:	R Garside, M Pitt, R Anderson, G Rogers, M Dyer, S Mealing, M Somerville, A Price, K Stein
Format:	Article
Language:	English
Published:	NIHR Journals Library 2007-11-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta11450

Similar Items

Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?
by: Luca Ricciardi, et al.
Published: (2022-06-01)

Prognostic effects of O6-Methylguanine DNA methyltransferase promoter hypermethylation in high-grade glioma patients with carmustine wafer implants
by: Mao-Yu Chen, et al.
Published: (2017-01-01)

Downregulation of Leucine-Rich Repeat-Containing 8A Limits Proliferation and Increases Sensitivity of Glioblastoma to Temozolomide and Carmustine
by: Sebastian Rubino, et al.
Published: (2018-05-01)

Progress of temozolomide in the treatment of recurrent high-grade gliomas
by: Jin-duo LI, et al.
Published: (2013-12-01)

Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV
by: Susan G. R. McDuff, et al.
Published: (2020-01-01)

Rationale and Clinical Implications of Fluorescein-Guided Supramarginal Resection in Newly Diagnosed High-Grade Glioma
by: Linda M. Wang, et al.
Published: (2021-05-01)

Carmustine-Induced Phosphatidylserine Translocation in the Erythrocyte Membrane
by: Kashif Jilani, et al.
Published: (2013-04-01)

A case of interstitial pneumonia caused by carmustine
by: Zhiwei WANG, et al.
Published: (2008-08-01)

Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas
by: Ibrahim eQaddoumi, et al.
Published: (2014-04-01)

Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas
by: Tracy L. Luks, et al.
Published: (2018-08-01)

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
by: Jie Chen, et al.
Published: (2022-11-01)

Fluorescein-guided resection of newly diagnosed high-grade glioma: Impact on extent of resection and outcome
by: Karl-Michael Schebesch, et al.
Published: (2022-01-01)

Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling
by: R Garside, et al.
Published: (2006-03-01)

Synergistic Effect of Perampanel and Temozolomide in Human Glioma Cell Lines
by: Andrea Salmaggi, et al.
Published: (2021-05-01)

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature
by: Jennifer Jeck, et al.
Published: (2018-01-01)

The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation
by: R Garside, et al.
Published: (2007-05-01)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
by: Georges Noël, et al.
Published: (2013-09-01)

Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation
by: Antoine Schernberg, et al.
Published: (2018-03-01)

A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas
by: Lawrence S. Lamb, et al.
Published: (2021-10-01)

A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy
by: Yanzhi Wan, et al.
Published: (2023-11-01)

Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas
by: Zewei Tu, et al.
Published: (2022-09-01)

Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma
by: Liyun Zhong, et al.
Published: (2022-02-01)

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis
by: Qunying Yang, et al.
Published: (2021-12-01)

Effect of temozolomide and methylprednisolone on the radiosensitivity in radiotherapy of human brain glioma cells
by: Yu LI, et al.
Published: (2011-06-01)

Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines
by: Nina Simona Tresch, et al.
Published: (2021-11-01)

The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review
by: J. Dinnes, et al.
Published: (2001-01-01)

Carmustine enhances the anticancer activity of selenite in androgen-independent prostate cancer cells
by: Thamilselvan V, et al.
Published: (2012-11-01)

Connectomic profile and clinical phenotype in newly diagnosed glioma patients
by: Jolanda Derks, et al.
Published: (2017-01-01)

Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
by: Shigeo Ohba, et al.
Published: (2021-05-01)

Temozolomide Chronotherapy in Glioma: A Systematic Review
by: Jason L. Jia, et al.
Published: (2023-02-01)

The strategy for enhancing temozolomide against malignant glioma
by: Mitsutoshi eNakada, et al.
Published: (2012-08-01)

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
by: Ehsan Alimohammadi, et al.
Published: (2020-02-01)

Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma
by: Ryan Miller, et al.
Published: (2022-04-01)

Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy
by: Kleinberg L
Published: (2016-11-01)

High preoperative albumin-bilirubin score predicts poor survival in patients with newly diagnosed high-grade gliomas
by: Jie Zhang, et al.
Published: (2021-04-01)

High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase
by: Yanwei Liu, et al.
Published: (2021-08-01)

Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma
by: Shi H, et al.
Published: (2020-05-01)

Cost-Effectiveness of Short-Course Radiation Plus Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Among Elderly Patients in China and the United States
by: Jigang Chen, et al.
Published: (2021-09-01)

Temozolomide with Radiation Therapy in High Grade Brain Gliomas: Pharmaceuticals Considerations and Efficacy;A Review Article
by: Demetrios Chaldeopoulos, et al.
Published: (2009-04-01)

Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas
by: Alberto Azzalin, et al.
Published: (2017-04-01)